Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.
Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk Vertex Pharmaceuticals Incorporated (VRTX) is currently at $464.17, up $25.77 or 5.88% --Would ...
H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Get Pro-Level Earnings Insights Before the Market Moves In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc VRTX, defending its ...